Media Summary: We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the ... Drs. Michael Gibson, Rasha Al-Lamee and Javed Butler review the Day 1 late-breaking science from Drs. Michael Gibson, Suzanne Baron and Deepak Bhatt review the Day 2 late-breaking science from

Access Points Evolut Low Risk Acc 23 Wcc - Detailed Analysis & Overview

We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the ... Drs. Michael Gibson, Rasha Al-Lamee and Javed Butler review the Day 1 late-breaking science from Drs. Michael Gibson, Suzanne Baron and Deepak Bhatt review the Day 2 late-breaking science from Dr. Deepak Bhatt reviews the Day 3 late-breaking science from Thank you to everyone who joined us at the World Congress of Cardiology together with Register today to join the American College of Cardiology and the World Heart Federation for

Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Roberto Diletti ... In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from ... Dr. Vinod H. Thourani gives the trial summary of the PARTNER 3 and Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview ...

Photo Gallery

ACCess Points – EVOLUT LOW RISK | ACC.23/WCC
ACC 23: TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial
Day 1 | ACCess Points Daily Wrap Up at ACC.23/WCC
Day 2 | ACCess Points Daily Wrap Up at ACC.23/WCC
Day 3 | ACCess Points Daily Wrap Up at ACC.23/WCC
ACC.23/WCC Highlights
ACC Cardiology Hour From ACC.23 Together With WCC
ACC.23/WCC Prevention and Health Promotion Pathway
Reunite With Your Colleagues at ACC.23/WCC
ACC 23 Late-Breaker Discussion: The BIOVASC Trial
TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial
Overview of PARTNER 3 & Evolut Low Risk TAVR Trials
Sponsored
Sponsored
View Detailed Profile
ACCess Points – EVOLUT LOW RISK | ACC.23/WCC

ACCess Points – EVOLUT LOW RISK | ACC.23/WCC

ACCess Points

ACC 23: TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial

ACC 23: TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial

We are joined onsite by Dr John Forrest (Yale Valve Clinic, US) in this short video, who outlines the three-year outcomes of the ...

Sponsored
Day 1 | ACCess Points Daily Wrap Up at ACC.23/WCC

Day 1 | ACCess Points Daily Wrap Up at ACC.23/WCC

Drs. Michael Gibson, Rasha Al-Lamee and Javed Butler review the Day 1 late-breaking science from

Day 2 | ACCess Points Daily Wrap Up at ACC.23/WCC

Day 2 | ACCess Points Daily Wrap Up at ACC.23/WCC

Drs. Michael Gibson, Suzanne Baron and Deepak Bhatt review the Day 2 late-breaking science from

Day 3 | ACCess Points Daily Wrap Up at ACC.23/WCC

Day 3 | ACCess Points Daily Wrap Up at ACC.23/WCC

Dr. Deepak Bhatt reviews the Day 3 late-breaking science from

Sponsored
ACC.23/WCC Highlights

ACC.23/WCC Highlights

Thank you to everyone who joined us at the World Congress of Cardiology together with

ACC Cardiology Hour From ACC.23 Together With WCC

ACC Cardiology Hour From ACC.23 Together With WCC

In the latest installment of

ACC.23/WCC Prevention and Health Promotion Pathway

ACC.23/WCC Prevention and Health Promotion Pathway

Erin shares a personal story about

Reunite With Your Colleagues at ACC.23/WCC

Reunite With Your Colleagues at ACC.23/WCC

Register today to join the American College of Cardiology and the World Heart Federation for

ACC 23 Late-Breaker Discussion: The BIOVASC Trial

ACC 23 Late-Breaker Discussion: The BIOVASC Trial

Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by principal investigator, Dr Roberto Diletti ...

TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial

TCT 23: Four-Year Outcomes from the EVOLUT Low Risk Trial

In this succinct interview, we are joined by Dr Michael Reardon (Houston Methodist, US) to discuss the four-year outcomes from ...

Overview of PARTNER 3 & Evolut Low Risk TAVR Trials

Overview of PARTNER 3 & Evolut Low Risk TAVR Trials

Dr. Vinod H. Thourani gives the trial summary of the PARTNER 3 and

What's Hot at ACC.23? Late-breaking Science Preview

What's Hot at ACC.23? Late-breaking Science Preview

Prof Nicolas Van Mieghem and Dr Joost Daemen return with their critical review series, View from the Thoraxcenter, to preview ...